Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Deloitte
Accenture
Harvard Business School
UBS
Boehringer Ingelheim
Farmers Insurance

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,074,256

« Back to Dashboard

Which drugs does patent 9,074,256 protect, and when does it expire?

Patent 9,074,256 protects FANAPT and is included in one NDA.

This patent has five patent family members in four countries.
Summary for Patent: 9,074,256
Title:Method of predicting a predisposition to QT prolongation
Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Inventor(s): Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:13/263,076
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,074,256

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-001 May 6, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-002 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-003 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Vanda Pharms Inc FANAPT iloperidone TABLET;ORAL 022192-004 May 6, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,074,256

PCT Information
PCT FiledApril 05, 2010PCT Application Number:PCT/US2010/029943
PCT Publication Date:October 14, 2010PCT Publication Number: WO2010/117941

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Healthtrust
Colorcon
Farmers Insurance
Federal Trade Commission
US Army
Mallinckrodt
Teva
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.